pulmicort and Syndrome

To highlight a severe case of rhinotillexomania (compulsive nasal picking) and its potential to manifest as empty nose syndrome (ENS).. A single case report with the presentation and management of a patient with severe rhinotillexomania who presented with chronic obstructive symptoms. We review the current literature on rhinotillexomania and ENS.. This patient's manifestations mimic the obstructive symptoms of ENS, despite widely patent nasal passages.. This is the first report of rhinotillexomania manifesting with features of ENS.

Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Budesonide; Compulsive Behavior; Endoscopy; Humans; Humidifiers; Male; Mupirocin; Nasal Obstruction; Nasal Septal Perforation; Nose Diseases; Syndrome; Therapeutic Irrigation; Tomography, X-Ray Computed

In this study, a meta-analysis of randomized controlled trials comparing ursodeoxycholic acid (UDCA) monotherapy with combination therapies utilizing UDCA and budesonide was performed. We found that combination therapy with UDCA and budesonide was more effective than UDCA monotherapy for primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Moreover, compared to prednisone, budesonide has fewer side effects.

Topics: Budesonide; Chi-Square Distribution; Cholagogues and Choleretics; Drug Therapy, Combination; Glucocorticoids; Hepatitis, Autoimmune; Humans; Liver Cirrhosis, Biliary; Odds Ratio; Randomized Controlled Trials as Topic; Syndrome; Treatment Outcome; Ursodeoxycholic Acid

To investigated the objective indicators and potential genotypes for acute mountain sickness (AMS). 176 male subjects were evaluated for symptoms scores and physiological parameters at 3700 m. EPAS1 gene polymorphisms were explored and verified effects of potential genotypes on pulmonary function by inhaled budesonide. The incidence of AMS was 53.98% (95/176). The individuals who suffered from headache with anxiety and greater changes in heart rate (HR), the forced vital capacity (FVC), and mean flow velocity of basilar artery (Vm-BA), all of which were likely to develop AMS. The rs4953348 polymorphism of EPAS1 gene had a significant correlation with the SaO2 level and AMS, and a significant difference in the AG and GG genotype distribution between the AMS and non-AMS groups. The spirometric parameters were significantly lower, but HR (P = 0.036) and Vm-BA (P = 0.042) significantly higher in the AMS subjects with the G allele than those with the A allele. In summary, changes in HR (≥82 beats/min), FVC (≤4.2 Lt) and Vm-BA (≥43 cm/s) levels may serve as predictors for diagnosing AMS accompanied by high-altitude syndrome. The A allele of rs4953348 is a protective factor for AMS through HR and Vm-BA compensation, while the G allele may contribute to hypoxic pulmonary hypertension in AMS.

Topics: Acute Disease; Adult; Alleles; Altitude Sickness; Basic Helix-Loop-Helix Transcription Factors; Blood Pressure; Budesonide; Demography; Genetic Predisposition to Disease; Humans; Logistic Models; Male; Polymorphism, Single Nucleotide; Spirometry; Syndrome; Young Adult

Topics: Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Budesonide; Female; Hashimoto Disease; Hepatitis, Autoimmune; Humans; Liver Cirrhosis, Biliary; Middle Aged; Polyendocrinopathies, Autoimmune; Syndrome; Ursodeoxycholic Acid

Topics: Anti-Inflammatory Agents; Autoimmune Diseases; Budesonide; Cholagogues and Choleretics; Cholangitis, Sclerosing; Cholestasis, Intrahepatic; Disease-Free Survival; Drug Therapy, Combination; Humans; Liver Cirrhosis, Biliary; Liver Function Tests; Liver Transplantation; Syndrome; Ursodeoxycholic Acid

Topics: Anti-Inflammatory Agents; Budesonide; Cholagogues and Choleretics; Diagnosis, Differential; Drug Therapy, Combination; Dry Eye Syndromes; Female; Humans; Liver Diseases; Middle Aged; Syndrome; Ursodeoxycholic Acid; Xerostomia

In a previous, controlled study, it was shown that orally administered budesonide increases the absorptive capacity of the intestinal mucosa in patients with ileostomies caused by Crohn's disease. This open, nonrandomized study was designed to analyze this functional, not inflammation-dependent steroid-effect in the long-term course comparing exposure, withdrawal, and reexposure.. Phase 1: 23 patients without inflammatory activity of the disease received oral budesonide (3 mg t.i.d.) for at least four weeks (36.7 weeks; standard deviation, 45.3 weeks) because of high intestinal output syndrome. Phase 2: Medication was stopped for four weeks. Phase 3: Medication as in Phase 1. In each phase the weight of the ileostomy bags was measured with a spring balance before emptying and documented in a diary. Mean values per day and per week were calculated and the differences statistically evaluated by the Wilcoxon-(Pratt)-test.. Comparing the last week of Phase 1 to first week of Phase 2, a significant (P < 0.0001) increase of the intestinal output (295 g; standard deviation, 313 g) was observed after omitting budesonide. In contrast, comparing the last week of Phase 2 to Phase 3, a significant (P < 0.0001) decrease of the intestinal output by 323.7 g (standard deviation, 322.2 g) was noticed reaching the same level as in Phase 1.. These data show that the functional, inflammation-independent effect of budesonide on the intestinal mucosa is strongly correlated to the administration of the drug and may be maintained long-term. These results should be confirmed by a larger number of patients.

Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Budesonide; Crohn Disease; Female; Humans; Ileostomy; Male; Middle Aged; Statistics, Nonparametric; Syndrome; Treatment Outcome

A 78-year-old man was referred to our hospital complaining of chronic productive cough. Physical examination revealed yellowish, thin nails and pretibial edema. A chest computed tomograph showed bilateral bronchiectasis. A sinus radiograph showed the findings of chronic sinusitis. From these findings, yellow nail syndrome was diagnosed. Long-term low-dose macrolide therapy with 400 mg/day clarithromycin was started and his symptoms began to gradually improve. However, complete resolution of his symptoms was not achieved and fiberoptic bronchoscopy was performed. Transbronchial biopsy specimen obtained from the right second carina showed bronchial asthma-like findings such as eosinophilic infiltration, thickening of the basement membrane, mucosal edema and goblet cell hyperplasia. Airflow reversibility was not detected. Thus a diagnosis of coexistence of yellow nail syndrome and eosinohilic bronchial disease was established. Further improvement of his symptoms was achieved by additional therapy with 800 microg/day budesonide and 100 microg/day salmeterol. To the best of our knowledge, this is the first report of a case of yellow nail syndrome associated with eosinophilic bronchial disease successfully treated with long-term low-dose macrolides and inhaled corticosteroids.

Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bronchial Diseases; Bronchiectasis; Budesonide; Clarithromycin; Drug Therapy, Combination; Eosinophilia; Humans; Lymphedema; Male; Nail Diseases; Sinusitis; Syndrome